Hilleman’s Shigella Vaccine Moves To Trials In Europe, Africa In ‘Big Step Forward’
India’s Hilleman Laboratories’ pioneering vaccine to treat shigellosis, a form of dysentery that’s a leading killer of young children, is moving into clinical trials in Europe and Africa, but expected launch date has been pushed back in parallel.
You may also be interested in...
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Vaccine specialist Hilleman announces partnership with another Indian firm, Bharat Biotech, to develop, manufacture and commercialize its simpler and cheaper oral cholera vaccine.
Serum Institute has launched a cut-price oral thermostable rotavirus vaccine in India, but competitors like Hilleman Labs, also developing a heat-stable vaccine in the area, aren’t losing much sleep, for now at least. Serum has also introduced a rabies monoclonal antibody.